What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing.
BRCA1/2
genetic counseling
germline mutations
prostate cancer genetics
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
28
10
2019
accepted:
21
01
2020
pubmed:
7
2
2020
medline:
9
7
2020
entrez:
7
2
2020
Statut:
ppublish
Résumé
Guidelines have changed recently to include genetic counseling (GC) and/or genetic testing (GT) for all men with aggressive prostate cancer (PCa). This study aimed to identify what information men with PCa desire before and from GC. Focus groups were conducted with men who have PCa. Audio recordings were analyzed for themes related to GT, the information they desired from health care providers, and implications for family members. Thirty-seven men with PCa participated in seven focus groups. Nearly all men felt GT was beneficial and impactful for their family and themselves. Most men were unaware of the risks to female relatives associated with hereditary cancer. Participants discussed that genetics should be incorporated at an appropriate time of their diagnostic journey. This study showed that men valued GC and GT for personal and familial implications, and often did not associate PCa genetics with risk for female relatives to develop cancer. Consideration should be given to the GC timing in regard to where men are in their treatment process. Providers referring patients can leverage patient motivations and utilize their relationship with the patient to determine the appropriate timing and personalize discussion with the patient regarding GC and GT.
Sections du résumé
BACKGROUND
Guidelines have changed recently to include genetic counseling (GC) and/or genetic testing (GT) for all men with aggressive prostate cancer (PCa). This study aimed to identify what information men with PCa desire before and from GC.
METHODS
Focus groups were conducted with men who have PCa. Audio recordings were analyzed for themes related to GT, the information they desired from health care providers, and implications for family members.
RESULTS
Thirty-seven men with PCa participated in seven focus groups. Nearly all men felt GT was beneficial and impactful for their family and themselves. Most men were unaware of the risks to female relatives associated with hereditary cancer. Participants discussed that genetics should be incorporated at an appropriate time of their diagnostic journey.
CONCLUSION
This study showed that men valued GC and GT for personal and familial implications, and often did not associate PCa genetics with risk for female relatives to develop cancer. Consideration should be given to the GC timing in regard to where men are in their treatment process. Providers referring patients can leverage patient motivations and utilize their relationship with the patient to determine the appropriate timing and personalize discussion with the patient regarding GC and GT.
Identifiants
pubmed: 32027768
doi: 10.1002/pros.23959
pmc: PMC8195313
mid: NIHMS1552707
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
441-450Subventions
Organisme : NCI NIH HHS
ID : K08 CA234431
Pays : United States
Organisme : NCI NIH HHS
ID : K08CA234431
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Psychosom Med. 2004 Jan-Feb;66(1):42-8
pubmed: 14747636
Genet Test. 2002 Summer;6(2):115-8
pubmed: 12215250
Cancer. 2008 Nov 1;113(9):2464-70
pubmed: 18666213
Lancet. 2003 Mar 8;361(9360):859-64
pubmed: 12642065
J Urol. 2018 Jun;199(6):1510-1517
pubmed: 29288121
J Med Genet. 2000 Nov;37(11):866-74
pubmed: 11073541
Ann Oncol. 1997 Sep;8(9):857-63
pubmed: 9358935
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
Clin Genet. 2006 Dec;70(6):462-72
pubmed: 17100990
JAMA Oncol. 2019 Apr 1;5(4):523-528
pubmed: 30730552
J Natl Compr Canc Netw. 2017 Jan;15(1):9-20
pubmed: 28040716
Infect Agent Cancer. 2009 Feb 10;4 Suppl 1:S2
pubmed: 19208207
J Genet Couns. 2013 Oct;22(5):662-73
pubmed: 23677535
J Cancer Epidemiol. 2012;2012:298745
pubmed: 23150731
Clin Breast Cancer. 2019 Aug;19(4):e547-e555
pubmed: 31005475
Am J Med Genet. 2002 Jan 15;107(2):143-50
pubmed: 11807889
Oncol Nurs Forum. 2012 Mar;39(2):E101-11
pubmed: 22374498
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Cell. 2015 Jul 16;162(2):454
pubmed: 28843286
J Clin Oncol. 2015 Nov 1;33(31):3660-7
pubmed: 26324357
Oncologist. 2010;15(6):648-55
pubmed: 20507890
Eur J Hum Genet. 2010 Dec;18(12):1289-95
pubmed: 20648056
Psychooncology. 2017 Nov;26(11):1818-1824
pubmed: 28101941
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846